Table 1 COVID-19 critically ill patients’ socio-demographic, comorbidities and care characteristics
From: Psychological evaluation and support in COVID-19 critically ill patients: a feasibility study
Variables | n (%) | Mean ± SD | Median [IQR] |
|---|---|---|---|
Gender Women Men | 37 (100.0%) 7 (18.9%) 30 (81.1%) | ||
Age | 37 (100.0%) | 58.8 ± 11.3 | 59.4 [53.4–63.7] |
History of: Sleep disorders Psychiatric consultations On-going depression Past trauma or PTSD Past depression Drug addiction (cannabis) History of: Tobacco use COPD Asthma Chronic hypertension Diabetes Chronic heart condition Chronic coronary disease Chronic kidney disease Pharmacological treatment ACEi Diuretics Proton pump inhibitor Beta-blockers Statins Metformin Fibrates Benzodiazepine Serotonin reuptake inhibitor ARB Aspirin Lithium Anticoagulant Cordarone None | 33 (89.9%) 6 (18.2%) 5 (14.7%) 4 (12.2%) 4 (12.2%) 2 (6.1%) 1 (3.0%) 37 (100.0%) 13 (35.1%) 6 (16.2%) 3 (8.1%) 22 (59.5%) 8 (21.6%) 6 (16.2%) 5 (13.5%) 2 (5.4%) 37 (100.0%) 12 (32.4%) 11 (29.7%) 11 (29.7%) 9 (24.3%) 7 (18.1%) 6 (16.2%) 5 (13.5%) 5 (13.5%) 4 (10.8%) 3 (8.1%) 3 (8.1%) 2 (5.4%) 2 (5.4%) 1 (2.7) 7 (18.1%) | ||
Duration of symptoms before admission to ICU (days) | 37 (100.0%) | 8.0 ± 2.6 | 8 [7–9] |
Clinical respiratory distress: Yes No | 32 (86.5%) 5 (15.6%) 27 (84.4%) | ||
Thromboembolic event: Yes No | 37 (100.0%) 9 (24.3%) 28 (75.7%) | ||
Acute respiratory distress syndrome Mild Moderate Severe | 37 (100.0%) 11 (29.7%) 17 (50.0%) 9 (24.3%) | ||
Neutrophils/lymphocytes ratio Less than 3.7 More than 3.7 | 37 (100.0%) 6 (16.2%) 31 (83.8%) | ||
C-reactive protein (mg/L) Ferritin (µg/L) Lactate Dehydrogenase (UI/L) Albumin (g/L) Fibrinogen (g/L) D-dimers (mg/L) | 37 (100.0%) 33 (89.9%) 32 (86.5%) 35 (94.6%) 33 (89.9%) 32 (86.5%) | 152 ± 105 2,206 ± 2,043 468 ± 165 20 ± 5 8.5 ± 1.3 5,535 ± 10,478 | 140 [66–202] 1,470 [941–3,258] 450 [367–537] 21 [16–24] [7.3–9.8] 1,554 [802–5,084] |
Oro-tracheal intubation: Yes No | 37 (100.0%) 28 (75.7%) 9 (24.3%) | ||
Duration of intubation (days) | 28 (100.0%) | 39.9 ± 6.6 | 39 [38–40] |
Duration of sedation (days) | 28 (100.0%) | 19.0 ± 15.2 | 14 [9–22] |
Cumulative dose of midazolam (mg) | 24 (85.7%) | 1731 ± 2115 | 889 [364–2.188] |
Cumulative dose of propofol (mg) | 22 (78.6%) | 23.560 ± 27.083 | 12.392 [5.060–34.264] |
Cumulative dose of morphine (mg) | 22 (78.6%) | 1459 ± 2491 | 882 [230– 1.463] |
Cumulative dose of clonidine (mg) | 22 (78.6%) | 2.44 ± 2.18 | 1.81 [0.85–3.2] |
Cumulative dose of levomepromazine (mg) | 13 (46.4%) | 267 ± 350 | 173 [0–287] |
Use of prone positioning Yes No | 28 (100%) 17 (60.7%) 11 (39.3%) | ||
Use of nitrogen monoxide Yes No | 37 (100.0%) 3 (8.1%) 24 (91.9%) | ||
Use of norepinephrine Yes No | 37 (100.0%) 26 (70.3%) 11 (29.7%) | ||
Maximal dose of norepinephrine (µg/kg/min) | 22 (84.6%) | 0.30 ± 0.31 | 0.17 [0.11–0.41] |
Cumulative dose of norepinephrine (mg) | 23 (88.5%) | 85.9 ± 143.4 | 28.0 [9.5–94.5] |
Place of follow-up Home Rehabilitation center | 34 (91.9%) 20 (58.8%) 14 (41.2%) | ||
Psychometric evaluation at day 7 Significant depression Significant insomnia Significant anxiety | 32 (86.5%) 5 (15.6%) 4 (12.5%) 3 (9.4%) | ||
Psychometric evaluation at week 6 Significant depression Significant insomnia Significant anxiety | 17 (45.9%) 2 (11.8%) 3 (17.7%) 2 (11.8%) | ||
Psychometric evaluation at week 12 Significant depression Significant insomnia Significant anxiety Significant PTSD symptoms | 24 (64.9%) 5 (20.8%) 22 (59.5%) 3 (13.6%) 23 (62.2%) 3 (13.0%) 25 (67.6%) 2 (8.0%) | ||
Psychometric evaluation at week 24 Significant depression Significant insomnia Significant anxiety Significant PTSD symptoms | 19 (51.4%) 2 (10.5%) 2 (10.5%) 18 (48.6%) 4 (22.2%) 1 (5.6%) |